SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE TO/A
Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
(Amendment No. 4)
Advanced Accelerator Applications S.A.
(Name of Subject Company)
by
Novartis Groupe France S.A.
and
Novartis AG
(Name of Filing Persons (Offerors))
Ordinary Shares, par value 0.10 per share
(Title of Class of Securities)
F0R0DZ103
(CUSIP Number of Class of Securities)
American Depositary Shares, each of which represents 2 Ordinary Shares, par value 0.10 per share
(Title of Class of Securities)
00790T100*
(CUSIP Number of Class of Securities)
Felix R. Ehrat
Group General Counsel
Novartis AG
CH-4056 Basel
Switzerland
Telephone: +41-61-324-1111
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications on Behalf of Filing Persons)
Copy to:
George A. Casey
George Karafotias
Shearman & Sterling LLP
599 Lexington Avenue
New York, NY 10022
Telephone: +1 (212) 848-4000
Calculation of Filing Fee
Transaction Valuation |
|
Amount of Filing Fee |
U.S. $3,969,691,422 |
|
U.S. $494,227 |
(1) Estimated for purposes of calculating the amount of the filing fee only, in accordance with Rule 0-11(d) under the Securities Exchange Act of 1934, as amended (the Exchange Act). Calculated by adding (a) 2,370,107 ordinary shares of Advanced Accelerator Applications S.A. (AAA) issued and outstanding (the Ordinary Shares), multiplied by U.S. $41.00, the offer price per Ordinary Share, (b) 43,072,775 American Depositary Shares of AAA (each of which represents two Ordinary Shares) issued and outstanding (each, an ADS, and collectively, the ADSs), multiplied by U.S. $82.00, the offer price per ADS, (c) 7,767,585 Ordinary Shares subject to outstanding stock options with an exercise price less than U.S. $41.00 per share, multiplied by U.S. $41.00, the offer price per Ordinary Share, (d) 376,000 Ordinary Shares subject to outstanding free shares, multiplied by U.S. $41.00, the offer price per Ordinary Share, and (e) 162,500 Ordinary Shares subject to outstanding warrants, multiplied by U.S. $41.00, the offer price per Ordinary Share. The calculation of the filing fee is based on information provided by AAA as of December 1, 2017, with respect to the amount of Ordinary Shares and ADSs, and November 20, 2017, with respect to the amount of stock options, free shares and warrants.
(2) The filing fee was calculated in accordance with Rule 0-11 of the Exchange Act and Fee Rate Advisory #1 for fiscal year 2018, issued August 24, 2017, by multiplying the transaction valuation by 0.0001245.
x Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and date of its filing.
Amount Previously Paid: U.S. $494,227 |
Filing Party: Novartis AG |
Form or Registration No.: Schedule TO |
Date Filed: December 7, 2017 |
o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
x third-party tender offer subject to Rule 14d-1.
o issuer tender offer subject to Rule 13e-4.
o going-private transaction subject to Rule 13e-3.
o amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results of the tender offer: x
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
o Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
o Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)
* This CUSIP number is assigned to the Subject Companys American Depositary Shares, each representing two (2) Ordinary Shares.
This Amendment No. 4 (this Amendment) amends and supplements the Tender Offer Statement on Schedule TO filed with the Securities and Exchange Commission on December 7, 2017 (together with any amendments and supplements thereto, the Schedule TO), relating to the offer by Novartis Groupe France S.A., a société anonyme organized under the laws of France (Purchaser) and a direct and indirect wholly-owned subsidiary of Novartis AG, a company organized under the laws of Switzerland (Parent), to purchase all of the outstanding ordinary shares, nominal value 0.10 per share (each, an Ordinary Share, and collectively, the Ordinary Shares), including Ordinary Shares represented by American Depositary Shares (each of which represents two Ordinary Shares) (each, an ADS, and collectively, the ADSs, and together with the Ordinary Shares, the Company Shares), of Advanced Accelerator Applications S.A., a société anonyme organized under the laws of France (AAA), for U.S. $41.00 per Ordinary Share and U.S. $82.00 per ADS (each such amount, the Offer Price), in each case, payable net to the seller in cash, without interest, less any withholding taxes that may be applicable, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated December 7, 2017 (together with any amendments or supplements thereto, the Offer to Purchase), and in the accompanying Ordinary Share Acceptance Form (together with any amendments or supplements thereto, the Ordinary Share Acceptance Form) and American Depositary Share Letter of Transmittal (together with any amendments or supplements thereto, the ADS Letter of Transmittal, and together with the Offer to Purchase, the Ordinary Share Acceptance Form and other related materials, as each may be amended or supplemented from time to time, the Offer), as applicable.
This Amendment is being filed on behalf of Parent and Purchaser. All capitalized terms used in this Amendment and not otherwise defined have the respective meanings ascribed to them in the Schedule TO. Except as otherwise set forth in this Amendment, the information set forth in the Schedule TO remains unchanged and is incorporated herein by reference to the extent relevant to the items in this Amendment. This Amendment should be read together with the Schedule TO.
The items of the Schedule TO set forth below are hereby amended and supplemented as follows:
Items 1 through 9 and Item 11.
The Offer to Purchase and Items 1 through 9 and 11 of the Schedule TO, to the extent Items 1 through 9 and 11 incorporate by reference the information contained in the Offer to Purchase, are hereby amended and supplemented by adding the following paragraphs thereto:
The Subsequent Offer Period expired as scheduled at 12:00 midnight, New York City time, on January 31, 2018 (which was the end of the day on January 31, 2018). The Ordinary Shares Agent and ADS Tender Agent have advised that, as of the expiration of the Subsequent Offer Period, a total of 95,127,753 Ordinary Shares (including Ordinary Shares represented by ADSs) were validly tendered during the initial offer period and the Subsequent Offer Period taken together, representing approximately 98.7% of the outstanding Ordinary Shares (including Ordinary Shares represented by ADSs). Purchaser has accepted for payment and has promptly paid (or will promptly pay) for all Company Shares validly tendered during the Subsequent Offer Period.
The press release announcing the expiration of the Subsequent Offer Period is attached hereto as Exhibit (a)(5)(E).
Item 12. Exhibits.
Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibit:
(a)(5)(E) Press Release issued by Novartis AG on February 1, 2018.
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 1, 2018
|
NOVARTIS GROUPE FRANCE S.A. | ||
|
|
|
|
|
|
|
|
|
By: |
/s/ Ramon Zapata | |
|
|
Name: |
Ramon Zapata |
|
|
Title: |
As Attorney |
|
|
|
|
|
|
|
|
|
By: |
/s/ Benjamin Brod | |
|
|
Name: |
Benjamin Brod |
|
|
Title: |
As Attorney |
|
|
|
|
|
|
|
|
|
NOVARTIS AG | ||
|
|
| |
|
|
| |
|
By: |
/s/ Keren Haruvi | |
|
|
Name: |
Keren Haruvi |
|
|
Title: |
As Attorney |
|
|
|
|
|
|
|
|
|
By: |
/s/ Jonathan Emery | |
|
|
Name: |
Jonathan Emery |
|
|
Title: |
As Attorney |
[Signature Page Schedule TO/A]
Exhibit (a)(5)(E)
Novartis International AG | |
Novartis Global Communications | |
CH-4002 Basel | |
Switzerland | |
| |
|
http://www.novartis.com |
MEDIA RELEASE · COMMUNIQUE AUX MEDIAS · MEDIENMITTEILUNG
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
Basel, February 1, 2018 Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all of the outstanding ordinary shares (Ordinary Shares), including Ordinary Shares represented by American Depositary Shares (ADSs), of Advanced Accelerator Applications S.A. (NASDAQ: AAAP) (AAA), for a price of USD 41.00 per Ordinary Share and USD 82.00 per ADS, in each case payable net to the seller in cash, without interest (the Offer). The subsequent offering period for the Offer, which commenced on January 22, 2018, expired as scheduled at 12:00 midnight, New York City Time, on January 31, 2018.
The Bank of New York Mellon, as ADS tender agent for the Offer, and Banque Transatlantique S.A., as Ordinary Shares agent for the Offer, have advised that, as of the expiration of the subsequent offering period, 95,127,753 Ordinary Shares (including Ordinary Shares represented by ADSs) were validly tendered during the initial offering period and subsequent offering period taken together, representing approximately 98.7% of all outstanding Ordinary Shares (including Ordinary Shares represented by ADSs). Novartis Groupe France S.A. has accepted for payment and has promptly paid (or will promptly pay) for all Ordinary Shares and ADSs validly tendered during the subsequent offering period.
Additional Information
This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities. On December 7, 2017, Novartis Groupe France S.A. and Novartis AG filed a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission (the SEC) and AAA filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC, in each case, with respect to the Offer. The Tender Offer Statement (including the Offer to Purchase, accompanying Ordinary Share Acceptance Form and ADS Letter of Transmittal and other offer documents) and the Solicitation/Recommendation Statement, along with any amendments or supplements to each, contain important information that should be read carefully before any decision is made with respect to the Offer. Those materials and all other documents filed by, or caused to be filed by, Novartis AG, Novartis Groupe France S.A. or AAA with the SEC will be available at no charge on the SECs website at www.sec.gov. The Tender Offer Statement on Schedule TO and related materials may be obtained for free under the InvestorsFinancial Data section of the Novartis website at https://www.novartis.com/investors/financial-data/sec-filings. The Solicitation/Recommendation Statement on Schedule 14D-9 and such other documents may be obtained for free from AAA under the Investor Relations section of AAAs website at http://investorrelations.adacap.com/.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as tender offer, commenced, offer, will, subject to, conditions, or similar expressions, or by express or implied discussions regarding the potential outcome of the tender offer for AAA commenced by Novartis. You should not place undue reliance on these
statements. Such forward looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the proposed acquisition described in this press release will be completed, or that it will be completed as currently proposed, or at any particular time. In particular, our expectations could be affected by, among other things: regulatory actions or delays or government regulation generally, including potential regulatory actions or delays relating to the completion of the potential acquisition described in this release; uncertainties regarding actual or potential legal proceedings, including, among others, potential legal proceedings with respect to the proposed acquisition; and other risks and factors referred to in Novartis AGs current Form 20-F on file with the SEC. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis and @NovartisCancer at https://twitter.com/novartiscancer
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Eric Althoff |
Kristen Klasey |
Novartis Global Media Relations |
Novartis Division Communications |
+41 61 324 7999 (direct) |
+862 778 4763 (direct) |
+41 79 593 4202 (mobile) |
+862 754 1732 (mobile) |
eric.althoff@novartis.com |
kristen.klasey@novartis.com |
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central |
|
North America |
|
Samir Shah |
+41 61 324 7944 |
Richard Pulik |
+1 212 830 2448 |
Pierre-Michel Bringer |
+41 61 324 1065 |
Cory Twining |
+1 212 830 2417 |
Thomas Hungerbuehler |
+41 61 324 8425 |
|
|
Isabella Zinck |
+41 61 324 7188 |
|
|